Alcobra Ltd. to Provide Second Quarter 2013 Financials and Business Update on August 6th
TEL AVIV, Israel, July 24, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), today announced that the company will release results for its second quarter ended June 30, 2013 on Tuesday, August 6, 2013.
The company will host a conference call on Tuesday, August 6th at 9:00 a.m. Eastern Time (4:00 p.m. Israeli Time) featuring remarks by Yaron Daniely, President and CEO of Alcobra. The conference call will be available via webcast and can be accessed through the Alcobra website, http://www.alcobra-pharma.com/events.cfm. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. To dial into the conference call, please dial 1-877-375-4189 (U.S. and Canada) or 1-973-935-2046 (Internationally).
For those unable to listen to the live event, an archive of the conference call will be available on the Alcobra website, http://www.alcobra-pharma.com/events.cfm. A telephonic playback of the conference call will be available for a week after the call by calling 1-855-859-2056 (U.S. and Canada) and 1-404-537-3406 (Internationally); and use the passcode: 20461839.
About Alcobra Ltd.
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder. MG01CI has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder. The company was founded in 2008 and is headquartered in Tel Aviv, Israel.
Forward Looking Statements
This press release contains forward-looking statements. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties, including, among others, risks that could cause results to differ materially from those expected by the management of Alcobra Ltd. More detailed information about the risks and uncertainties affecting Alcobra Ltd.is contained under the heading "Risk Factors" in Alcobra Ltd.'s registration statement on Form F-1 filed with the SEC, which is available on the SEC's web site, www.sec.gov. Alcobra Ltd. undertakes no obligation to update or revise any forward-looking statements.
CONTACT: U.S. Investor Contacts:
KCSA Strategic Communications
Jeffrey Goldberger / Garth Russell
+1 212.896.1249 / +1 212.896.1250
jgoldberger@kcsa.com / grussell@kcsa.com
Israel Investor Contact:
Investor Relations Ltd.
Moran Meir-Beres
+011972-3-5167620
moran@km-ir.co.il
